Intercept Pharma (ICPT) Estimates Raised At Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Intercept Pharmaceuticals (ICPT) PT Raised to $149 at Cowen
February 19, 2019 4:12 PM ESTCowen analyst Ritu Baral raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $149.00 (from $120.00) while maintaining a Outperform rating.
The analyst commented, "ICPT's Ph3 NASH trial REGENERATE reported positive data this morning, achieving statistically significant fibrosis (with no... More
Intercept Pharmaceuticals (ICPT) PT Raised to $248 at Wedbush
February 19, 2019 1:57 PM ESTWedbush analyst Liana Moussatos raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $248.00 (from $220.00) while maintaining a Outperform rating.
... MoreIntercept Pharmaceuticals (ICPT) PT Raised to $175 at Oppenheimer; 'REGENERATE Top Line Sparks Joy'
February 19, 2019 1:03 PM ESTOppenheimer analyst Jay Olson raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $175.00 (from $140.00) while maintaining a Outperform rating.
The analyst commented, "Top line results from the Ph3 REGENERATE study of OCA in NASH were stat sig for Fibrosis... More
Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company on Positive Positive Phase 3 REGENERATE NASH Trial
February 19, 2019 10:42 AM ESTNeedham & Company analyst Alan Carr reiterated a Buy rating and $150 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the company announced this morning that one of the two primary endpts of the Phase 3 REGENERATE trial in F2/F3 NASH was met w/ the highest dose tested (25mg QD Obeticholic... More
